Linezolid is approved for treating specific bacterial infections. Its primary indications include community-acquired pneumonia and certain skin and skin structure infections, such as those caused by methicillin-resistant Staphylococcus aureus (MRSA) [1][2]. It is also used for vancomycin-resistant Enterococcus faecium infections [1][2].
What types of infections does linezolid treat?
Linezolid is effective against Gram-positive bacteria. This includes bacteria like MRSA and vancomycin-resistant Enterococcus species, which can be challenging to treat with other antibiotics [1][2].
How does linezolid work?
Linezolid is an oxazolidinone antibiotic. It works by inhibiting bacterial protein synthesis, preventing bacteria from growing and multiplying [3]. It binds to the 50S ribosomal subunit of bacteria, blocking the formation of the initiation complex required for protein production [3].
When does linezolid lose patent protection?
The patent exclusivity for linezolid has expired in many regions, allowing for the development of generic versions. For instance, patents related to linezolid have expired, and its marketing exclusivity in the United States ended in 2007 [4].
Who manufactures linezolid?
Original development and marketing of linezolid were by Pharmacia & Upjohn, which later became part of Pfizer. Today, multiple pharmaceutical companies produce generic versions of linezolid [5].
What are the risks associated with taking linezolid?
Linezolid can cause serious side effects, including myelosuppression (low blood cell counts), which can lead to anemia, thrombocytopenia (low platelets), and neutropenia (low white blood cells) [1]. It can also interact with monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs), potentially leading to serotonin syndrome, a life-threatening condition [1][2]. Other potential side effects include diarrhea, nausea, and headache [1].
What clinical data supports linezolid's use?
Clinical trials have demonstrated linezolid's efficacy in treating infections caused by susceptible Gram-positive organisms. Studies have shown comparable cure rates to vancomycin for skin and skin structure infections and effectiveness against hospital-acquired pneumonia and ventilator-associated pneumonia caused by MRSA and Streptococcus pneumoniae [6][7].
Can children use linezolid?
Linezolid is approved for use in pediatric patients for certain infections, with dosing adjusted based on age and weight [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020926s026,021002s007,021209s003lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/books/NBK448183/
[3] https://pubmed.ncbi.nlm.nih.gov/12880447/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa020544
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847488/